Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Intensity Allo-PBSCT with Busulfan, Melphalan, and Alemtuzumab
NCT00997386Phase 2Completed
- Sponsor
- University of Arizona
- Start
- Sep 2009
- Primary completion
- Apr 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, busulfan, melphalan in hematologic neoplasms, multiple myeloma (MM), aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), sponsored by University of Arizona. Started Sep 2009; status: completed.
02
Drugs
alemtuzumabbusulfanmelphalan
03
Conditions
hematologic neoplasmsmultiple myeloma (MM)aplastic anemiaparoxysmal nocturnal hemoglobinuria (PNH)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00997386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00997386.